Basilea Looks To Progress Cancer Pipeline As It Expands Zevtera Use
Ceftobiprole Approved In China
Switzerland’s Basilea Pharmaceutica is progressing its lead oncology candidates and a second late-stage US clinical trial of ceftobiprole in difficult-to-treat infections.
You may also be interested in...
The first pivotal Phase III study required for US approval of Basilea’s ceftobiprole has reported positive topline results; a second study is expected to read out in 2021.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Two European pharmaceutical companies, UCB and Merck KGaA, are exploring artificial intelligence in different ways, the first for drug discovery and the second on a fundamental level.